ORPHA:527276
Encephalopathy due to mitochondrial and peroxisomal fission defect
Publications
3,972
Trials
0
Interventional, condition-specific
Researchers
267
Distinct authors in sample
Gene link
DNM1L, MFF
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare disease characterized by a variable comprising delayed psychomotor development or neurodevelopmental regression, , , microcephaly, optic atrophy, pyramidal signs, and peripheral , among others. Age of onset and disease severity are also variable with some cases taking a fatal course in early infancy. Serum lactate levels may be elevated. Reported brain imaging findings include abnormal signals in the basal ganglia, cerebral and/or cerebellar atrophy, and white matter abnormalities.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0054865
- UMLS:C5681458
Additional Mondo synonyms (2)
encephalopathy due to defective mitochondrial and peroxisomal fission · encephalopathy due to mitochondrial and peroxisomal fission defect
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — DNM1L, MFF
- LiteraturePresent
3,972 matched papers (3,097 in last 10 years) Source
- Phenotype characterisedPresent
117 HPO annotations (e.g. Pain insensitivity; Broad thumb; Elevated circulating hexacosanoic acid concentration) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (DNM1L, MFF).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
117
Associated phenotypes · MONDO:0054865
- Pain insensitivity
- Broad thumb
- Elevated circulating hexacosanoic acid concentration
- Drooling
- Optic disc pallor
Showing 5 of 117 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3,972
3,972 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3,972 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
3,097 in the last 10 years · low confidence
Phrase hits: 42 · MeSH hits: 0
Who's working on it?
267
Distinct author names in 42 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Bellen HJ3 papers · 2024
Department of Molecular and Human Genetics, Howard Hughes Medical Institute and Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030, USA, Neurological Research Institute, Texas Children Hospital, Houston, TX 77030, USA.
Papers in Europe PMC - 02Gama V3 papers · 2025
Vanderbilt University, Cell and Developmental Biology, Nashville, TN 37232, USA.
Papers in Europe PMC - 03Li D3 papers · 2025
Department of Pediatric Neurology, Tianjin Children's Hospital/Tianjin University Children's Hospital, Tianjin, China.
Papers in Europe PMC - 04Mears JA3 papers · 2023
Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Papers in Europe PMC - 05Robak LA3 papers · 2019
Department of Molecular and Human Genetics, Neurological Research Institute, Texas Children Hospital, Houston, TX 77030, USA.
Papers in Europe PMC - 06Robertson GL3 papers · 2025
Vanderbilt University, Cell and Developmental Biology, Nashville, TN 37232, USA.
Papers in Europe PMC - 07
- 08Wangler MF3 papers · 2019
Department of Molecular and Human Genetics, Neurological Research Institute, Texas Children Hospital, Houston, TX 77030, USA michael.wangler@bcm.edu.
Papers in Europe PMC - 09Zhang Z3 papers · 2025
Department of Pediatric Neurology, Tianjin Children's Hospital/Tianjin University Children's Hospital, Tianjin, China.
Papers in Europe PMC - 10Assia Batzir N2 papers · 2019
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Encephalopathy due to mitochondrial and peroxisomal fission defect — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Encephalopathy due to mitochondrial and peroxisomal fission defect" OR "encephalopathy due to defective mitochondrial and peroxisomal fission") OR ("DNM1L" OR "DNM1L syndrome" OR "DNM1L-related" OR "MFF syndrome" OR "MFF-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Encephalopathy due to mitochondrial and peroxisomal fission defect" OR "encephalopathy due to defective mitochondrial and peroxisomal fission"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (3972) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T18:04:17.268Z